Recently a drug trial in the Netherlands in which the efficacy of oral sildenafil was compared to placebo in women bearing children with fetal growth restriction was stopped early because of very harmful side effects to the babies. There were quite some unwanted and unscientific aspects related to this study and the manner in which the side effects were communicated to the patients and the community. These have not gained the attention they ought to have. We therefore made an analysis of the basic problems which aims to prevent that the trust in medical research will be weakened.
BowerSKingdomJCampbellS. Objective and subjective assessment of abnormal uterine artery Doppler flow velocity waveforms. Ultrasound Obstet Gynecol. 1998;12:260–4.
5.
MooreRJStrachanBKTylerDJDuncanKRBakerPNWorthingtonBSIn utero perfusing fraction maps in normal and abnormal restriction pregnancy measured using IVIM echo-planner MRI. Placenta. 2000;21:726–32.
GolderSLokeYKWrightKNormanG. Reporting of adverse events in published and unpublished studies of health care interventions: Systematic review. PLOS Med. 2016;13:e1002127.
16.
BarstRJIvyDDGaitanGA randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naïve children with pulmonary arterial hypertension. Circulation. 2012;125:324–34.
RyhammerPKShekerdemianLSPennyDJRavnHB. Effect of intravenous sildenafil on pulmonary hemodynamics and gas exchange in the presence and absence of acute lung injury in piglets. Pediatr Res. 2006;59:762–6.
